Chung Tsen Hsueh, MD
Hematology & Oncology · Loma Linda, CANPI 1386671907
Payments from drug & device makers
Across 17 payments — averaging $268.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- QED Therapeutics, Inc.$2K
- Incyte Corporation$1K
- Bayer$900
- BTG International Inc.$219
- Epizyme, Inc.$45
- Pharmacyclics LLC, An Abbvie Company$28
- plus $52 from 3 others
What the payments were for
- Consulting fees$2,27087%
- Food & beverage$30011%
- Education$452%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| QED Therapeutics, Inc. | 8 | $1,950 |
| Incyte Corporation | 1 | $1,370 |
| Bayer | 1 | $900 |
| BTG International Inc. | 2 | $219 |
| Epizyme, Inc. | 1 | $45 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $28 |
| Amgen | 1 | $21 |
| Novartis | 1 | $17 |
| Array Biopharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,565 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 13 | $360,377 |
| FruzaqlaFruquintinib | 14 | $332,236 |
| SprycelDasatinib | 14 | $233,945 |
| LonsurfTrifluridine/Tipiracil Hcl | 19 | $211,269 |
| Lenalidomide | 12 | $179,526 |
| ZarxioFilgrastim-Sndz | 16 | $19,797 |
| EliquisApixaban | 14 | $13,567 |
| XareltoRivaroxaban | 13 | $7,424 |
| Imatinib Mesylate | 33 | $2,105 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 63 | $1,667 |
| Ondansetron OdtOndansetron | 55 | $1,286 |
| Potassium Chloride | 76 | $1,174 |
| LoperamideLoperamide Hcl | 46 | $1,109 |
| Prochlorperazine Maleate | 65 | $981 |
| Oxycodone Hcl | 37 | $653 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Loma Linda
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.